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A recently discovered dimension of post-transcriptional gene regulation involves co-regulatory crosstalk between
RNA transcripts, which compete for common pools of microRNA (miRNA) molecules. These competing endogenous
RNAs (ceRNAs), or natural miRNA sponges, have an active role in regulating miRNA availability within the cell and
form intertwined regulatory networks. Recent reports have implicated diverse RNA species including protein-coding
messenger RNAs and non-coding RNAs as ceRNAs in human development and diseases including human cancer. In
this review, we discuss the most recent discoveries that implicate natural miRNA decoys in human cancer biology,
as well as exciting advances in the study of ceRNA networks and dynamics. The structure and topology of intricate
genome-scale ceRNA networks can be predicted computationally, and their dynamic response to fluctuations in
ceRNA and miRNA levels can be studied via mathematical modeling. Additionally, the development of new
methods to quantitatively determine absolute expression levels of miRNA and ceRNA molecules have expanded the
capacity to accurately study the efficiency of ceRNA crosstalk in diverse biological models. These major milestones
are of critical importance to identify key components of ceRNA regulatory networks that could aid the development
of new approaches to cancer diagnostics and oligonucleotide-based therapeutics.
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MicroRNAs (miRNAs) comprise a class of small non-
coding RNAs implicated in post-transcriptional RNA
regulation. These RNA molecules are approximately 22
nt in length and bind to miRNA response elements
(MREs) on target transcripts through sequence comple-
mentarity, usually inducing repression or destabilization
of the target transcript [1,2]. A single miRNA can regulate
up to thousands of target transcripts [3], and miRNAs can
act in a combinatorial manner by binding to separate
MREs on a single RNA transcript. MiRNA-mediated regu-
lation is one of the most widespread post-transcriptional
regulatory mechanism in eukaryotes, and is estimated to
affect the majority of human transcripts [4,5]. In fact,
accumulating evidence highlights the role of miRNA-
mediated regulation in cell growth, differentiation, pro-
liferation, and apoptosis [6]. Furthermore, miRNAs* Correspondence: yvonnetay@nus.edu.sg
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article, unless otherwise stated.have been implicated in many diseases including cancer
[7,8]. Alterations in the miRNA balance in the cell can
lead to dysregulation of tumor suppressor genes and/or
oncogenes controlled by aberrantly expressed miRNAs,
leading to cancer [9,10].
Although the miRNA field is relatively young, a
miRNA-based therapeutic has already entered phase 2
clinical trials [11,12]. In cancer, therapeutic strategies
targeting miRNAs can be divided into two opposing ap-
proaches: (1) MiRNA mimics, which restore the function
of tumor suppressive miRNAs; and (2) MiRNA inhibitors,
which antagonize the function of oncogenic miRNAs. This
can be achieved either by using chemically-modified RNA
oligos which mimic or inhibit miRNA function or by
artificially generated ‘miRNA sponges’ [13-15]. These
exogenously expressed transcripts contain tandem repeats
of MRE sites that allow them to specifically bind a distinct
miRNA or combination of miRNAs. Once the miRNA(s)
of interest has been decoyed, it will be unavailable to bind
to its targets, leading to the effective de-repression of these
transcripts [13,16].ed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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regulate the expression of endogenous miRNAs, it has
been recently demonstrated that endogenous transcripts
which contain MREs can interact and co-regulate each
other through competition for common miRNA pools in
the cell, acting as endogenous miRNA sponges or com-
peting endogenous RNAs (ceRNAs) [17,18]. This intri-
cate interplay between diverse RNA species, whereby
one transcript can reciprocally modulate the expression
of another transcript by sequestering shared miRNAs,
has been referred to as ceRNA crosstalk [19]. CeRNA
activity has been attributed to both protein-coding and
non-coding RNA transcripts. Examples of this compet-
ing endogenous crosstalk have been described in plants,
such as Arabidopsis thaliana [20], the primate virus
Herpesvirus saimiri [21], zebrafish [22], and mice as
well as humans [23,24].
The implication of ceRNAs in humans has been ex-
tended from normal cell differentiation to tissue develop-
ment and pathology, since relevant ceRNA functionality
has been associated with the self-renewal capacity of
embryonic stem cells [25], muscle differentiation [23],
idiopathic pulmonary fibrosis [26], and liver cancer [27]
among other biological processes. Although ceRNA re-
search is in its infancy, accumulating evidence suggests
that this additional dimension of post-transcriptional gene
regulation, in which RNA transcripts titrate miRNA avail-
ability, represents a biologically relevant, well-conserved
and widespread mechanism of regulation in eukaryotes.
Competing endogenous RNAs in cancer
Several examples of MRE-containing non-coding RNA
transcripts acting as ceRNAs have been described. This
suggests that many long non-coding RNAs may poten-
tially function as ceRNAs, and that the analysis of ceRNA
interactions may facilitate the functional characterization
of such non-coding transcripts. Interestingly, there is a
widespread prevalence of somatic mutations, gross genetic
alterations, and chromosome rearrangements affecting the
non-coding genome in cancer [28,29]. Additionally, cancer
cells often express alternative isoforms of mRNAs with
shorter 3′UTR regions [30]. These events may lead to the
mutation or loss of MREs, which will not only affect
miRNA regulation in cis but also the associated ceRNA in-
teractions. The dysregulation of ceRNA interactions may,
in turn, have profound implications for cancer initiation,
maintenance, or progression. Thus, it is perhaps unsur-
prising that significant research efforts thus far on
ceRNA-mediated post-transcriptional regulation have fo-
cused on cancer initiation, maintenance, or progression
(Figure 1). The role of ceRNAs in cancer biology has been
reviewed in detail elsewhere [19,31]. As such, in this re-
view, we will focus mainly on the most recent develop-
ments in the field.The most extensively characterized ceRNA network
(ceRNET) is perhaps that of the tumor suppressor gene
PTEN. The processed pseudogene PTENP1, which is
highly homologous to PTEN and shares many of its 3′
UTR MREs, was the first non-coding transcript shown
to post-transcriptionally regulate PTEN expression in a
miRNA-dependent manner [17]. In a recent study,
PTENP1 was reported to be downregulated in clear-cell
renal cell carcinoma and shown to regulate PTEN expres-
sion. PTENP1 tumor suppressive properties were due in
part to sequestration of miR-21, providing additional sup-
port for the functional relevance of PTENP1 as a tumor
suppressive ceRNA for PTEN [32]. Additional studies
have identified various mRNA transcripts that function as
PTEN ceRNAs and regulate PTEN expression in a 3′UTR
and miRNA-dependent manner in brain, breast, colon,
prostate, and skin cancers [33-36].
Recent reports have provided increasing support for
the ceRNA activity of long non-coding RNAs (lncRNAs),
suggesting that the characterization of ceRNA networks
may enable researchers to systematically study the func-
tion of these largely uncharacterized RNA transcripts. In
addition, lncRNAs often display specific expression pat-
terns in different cell types, tissue types, developmental
stages, and disease [37], making them ideal candidates
for participating in finely tuned post-transcriptional
regulation.
One such example is linc-RoR, which had already been
shown to control self-renewal and maintain pluripotency
of human embryonic stem cells by acting as a miR-145
‘sponge’ and thus controlling OCT4, NANOG, and
SOX2 expression [25]. Similarly, linc-RoR was found to
regulate expression of the same transcription factors in
endometrial cancer stem cells, and inhibit their differen-
tiation, in a miR-145 dependent manner [38].
Another example of lncRNA-mediated ceRNA regula-
tion involves the tumor suppressor gene BARD1. The
newly discovered lncRNA BARD1 9′L is transcribed
from an alternative intronic promoter of the BARD1
gene, and was found to share both miR-203 and miR-
101 MREs with BARD1 mRNA in their homologous 3′
UTRs [39]. Moreover, full-length BARD1 and cancer-
associated BARD1 mRNAs were downregulated by miR-
203 and miR-101, and lncRNA BARD1 9′L counteracted
the effect of these miRNAs. These data support a role
for BARD1 9′L as a tumor suppressor transcript through
its ceRNA activity.
Conversely, the ceRNA activity of lncRNAs has also
been shown to have an oncogenic effect: The lncRNA
HOTAIR was shown to display ceRNA activity in gastric
cancer cells, in which it was found to specifically bind the
tumor suppressor miR-331-3p, modulating HER2 de-
repression [40]. In addition, the authors observed an asso-
ciation of HOTAIR expression with cancer progression
Figure 1 Involvement of ceRNA-mediated regulation in human cancers. Schematic representation of a simplified ceRNA network with two
transcripts and one miRNA (blue circle), and the different cancers for which ceRNA activity has been experimentally verified (orange circles).
Different ceRNA subnetworks are represented by squares, where ceRNAs (in blue) interact among each other by binding and competing for
common miRNA molecule pools (in green). Validated ceRNA interactions have been reported for breast cancer [39,72-74], melanoma [35],
endometrial cancer [38], glioblastoma [36], liver cancer [27,74,75], gastric cancer [40,60], colorectal cancer [17,34,76], prostate cancer [17,34,39],
lung cancer [39,55], and lymphoma [41].
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advanced gastric cancer.
A very recent report explored the role of the BRAF
pseudogene (BRAFP1) in regulating the expression of BRAF
in a miRNA-dependent manner [41]. This study demon-
strated that BRAFP1 functions as a ceRNA for BRAF in
part by sponging miR-30a, miR-182, and miR-876, and that
the oncogenic effect of BRAFP1 overexpression in vitro was
at least partly mediated by the upregulation of BRAF
expression and subsequent activation of MAPK. More-
over, the authors presented a mouse model overex-
pressing full-length murine B-Raf pseudogene that
developed an aggressive malignancy resembling human
diffuse large B cell lymphoma. This study is the first
one to demonstrate the oncogenicity of a pseudogene
in an engineered mouse model, and provides further
in vivo support for the role of ceRNA-mediated miRNA
sequestration on cancer development.
Molecular considerations for ceRNA interactions
Although there are increasing reports describing bona
fide ceRNA interactions in diverse biological settings,
several open questions remain about the physiological
relevance of these interactions [42]. Factors such asmiRNA- and ceRNA-expression levels and subcellular
localization, number of shared MREs, and miRNA/ceRNA
binding affinity have all been suggested to modulate the
effectiveness of ceRNA crosstalk [18,43,44]. Indeed, it
has been shown that molecular interactions that are
dependent on titration mechanisms, such as ceRNA
crosstalk, usually display a threshold-like behavior
determined by the relative abundance of interacting
molecules [45].
Several recent reports have described various computa-
tional models that have shed light on the specific molecu-
lar requirements for effective ceRNA interactions both at
steady-state conditions, and in dynamic conditions when
the system transiently responds to perturbations around
the threshold level [46-50]. Using an in silicomathematical
mass-action model to determine the optimal conditions
for ceRNA interactions, Ala et al. identified several mo-
lecular determinants for effective ceRNA crosstalk [46].
These determinants include factors such as miRNA and
ceRNA expression levels, the number of MREs shared be-
tween ceRNAs, and the total number of MREs for the
miRNAs of interest. In an alternative approach, Figliuzzi
et al. utilized a minimal rate-equation-based model of
post-transcriptional regulation at steady-state levels to
Sanchez-Mejias and Tay Journal of Hematology & Oncology  (2015) 8:30 Page 4 of 9characterize the nature of ceRNA interactions [48]. Inter-
estingly, they suggest that ceRNA interactions can be ei-
ther symmetrical, whereby two ceRNAs co-regulate each
other, or asymmetrical, whereby one ceRNA regulates ex-
pression of the other in a unidirectional manner. In
addition to steady-state system assumptions, researchers
have harnessed various mathematical models to investi-
gate the dynamics of ceRNA crosstalk. Studies have de-
scribed the equilibrium phenomenon that the system
displays in the threshold proximity that is found at near
equimolar conditions [47], as well as the transient re-
sponse of the system to perturbations [49]. In addition, a
recent report presented a computational model to quanti-
tatively describe a minimum ceRNA network, and experi-
mentally validated the predictions in cultured human cells
using synthetic gene circuits [50].
Despite the differences in the mathematical approaches,
interaction parameters, and assumptions for these studies,
several common conclusions can be drawn. For instance,
optimal ceRNA-mediated regulation was observed to de-
pend heavily on the miRNA/ceRNA ratio [46,47,50], con-
sistent with quantitative experimental data demonstrating
that the optimal conditions for miRNA functionality
depended largely on miRNA/target relative abundance
[50,51]. Optimal ceRNA crosstalk, whereby one ceRNA
has the most striking effect on its interacting ceRNA part-
ners, was predicted to occur when miRNA and ceRNA
levels were near equimolarity [47,51] (Figure 2A). AnotherA
Figure 2 Molecular dynamics of ceRNA interactions. (A) Optimal molec
ratios. Schematic representation of a simplified ceRNA network involving tw
(orange and green circles) that bind to miRNA1 (orange) and miRNA2 (gre
a response in the expression of co-regulated ceRNAs only in a narrow miRNA
When miRNA concentration is in excess, the titration capacity of competing M
Conversely, in excess of ceRNA, most miRNA molecules will bind their MRE sit
miRNA/ceRNA ratios. (B) The presence of indirect interactions can amplify ceR
three ceRNAs and two (top panel) or three (bottom panel) miRNAs. When ceR
of ceRNA 1 upregulation on ceRNA 2 and ceRNA 3 levels may be amplified b
not involve a direct relationship between ceRNA 1 and either ceRNA 2 or ceRcommon finding was that the number of shared miRNAs
among RNA transcripts played an important role in deter-
mining the effectiveness of ceRNA crosstalk [46-48].
Interestingly, ceRNA crosstalk appeared to represent a
viable mechanism to achieve fast, positive changes in
transcript levels [49]. Additionally, mathematical models
predicted that ceRNA crosstalk could represent a power-
ful noise-processing mechanism in gene expression that
can lead to noise reduction or amplification [47,48].
These bioinformatic analyses suggest that ceRNAs may
potentially play a central role in post-transcriptional
regulation.
These mathematical models also led to some unex-
pected findings. For example, ceRNAs may interact with
other ceRNAs directly and/or indirectly [46]. In the
hypothetical network depicted in Figure 2B, ceRNA 1 in-
teracts directly with ceRNA 2 via miRNA 1, and directly
with ceRNA 3 via miRNA 2. In a situation where ceRNA
2 also interacts with ceRNA 3 via an additional miRNA
3 (Figure 2B, bottom panel), then ceRNA 1 would inter-
act indirectly with ceRNA 2 via miRNA 2-ceRNA 3-
miRNA 3. Ala et al. found that such indirect interactions
were surprisingly effective at enhancing ceRNA cross-
talk, and that ceRNAs were able to respond to changes
in other ceRNAs even in the absence of shared miRNAs
[46,47]. The relevance of indirect interactions to overall
ceRNET architecture was corroborated by an independ-
ent study analyzing the interactions between distantB
ular conditions for effective ceRNA crosstalk depend on miRNA/ceRNA
o transcripts (with blue backbones) harboring two different MRE sites
en), respectively. Variations in ceRNA expression levels would generate
concentration window, and only for a range of ceRNA concentration.
RE is diminished and no effect would be observed on ceRNA crosstalk.
es, and the system would be insensitive to changes in the relative
NA crosstalk. Schematic representation of two ceRNA networks involving
NA 2 is able to co-regulate ceRNA 3 by sequestering miRNA 3, the effect
y this secondary crosstalk. This is termed an indirect interaction as it does
NA 3.
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timal molecular conditions, ceRNETs may be altered by
changes in the transcription rate of a single key ceRNA
[47], and this effect is predicted to be greater for highly
expressed ceRNAs [46]. These findings have enormous
implications not only for the molecular study of cancer
gene dysregulation but also for the exploration of
miRNA sponges as new therapeutic tools.
As an essential complement to the above-mentioned
analyses, which were largely computational, a number of
recent studies have sought to experimentally quantify
miRNA and target cellular abundance as well as miRNA
target affinity. In a landmark study, a quantitative assess-
ment of genome-wide miRNA regulation in the context of
ceRNA crosstalk was performed in embryonic and mesen-
chymal stem cells, using Ago2 individual-nucleotide reso-
lution UV crosslinking and immunoprecipitation, together
with absolute miRNA and mRNA quantification [53].
They found that miRNA/ceRNA ratios determined not
only Ago accumulation to its different affinity sites but
also the susceptibility and threshold of miRNA-dependent
ceRNA regulation. Single-cell miRNA reporter assays con-
firmed that low miRNA/ceRNA pool ratios, such as those
found endogenously for the miR-92/25 family, possess an
increased susceptibility for ceRNA regulation. On the
other hand, highly expressed miRNA families such as
miR-294 and let-7 were found to be insensitive to changes
in relative ceRNA abundance in this experimental model.
These data establish an experimental framework for the
biochemical analysis of ceRNA interactions and provide
critical experimental support for the physiological rele-
vance of ceRNA crosstalk.
As discussed above, several computational and experi-
mental studies have suggested that high abundance miR-
NAs may not be susceptible to effective ceRNA
regulation. However, exceptions to this hypothesis may
exist. The HMGA2 mRNA was shown to decoy the
highly abundant let-7 miRNA family, thus regulating
TGFBR3 expression and enhancing TGF-β signaling
[54]. This ceRNA activity of the HMGA2 transcript was
proposed to promote lung cancer progression. Critically,
the authors found that HMGA2 and TGFBR3 transcripts
were expressed at similar levels, and that total let-7 fam-
ily expression was within an order of magnitude of these
transcripts in the lung cancer cell line tested. These data
suggest that in certain settings, even highly abundant
miRNAs such as let-7 may be effectively regulated by
ceRNA interactions. Furthermore, the precise topology
of ceRNETs may result in bona fide ceRNA regulation
which may seem improbable based purely on specific
miRNA/mRNA ratios. For example, mathematical mod-
eling has predicted that effective interactions between
two ceRNAs can be mediated by a large number of
shared miRNAs, which may each only have a weak effecton ceRNA levels [48]. This suggests that future studies
focused on high-throughput techniques to identify and
characterize interconnected ceRNA networks will lead
to important insights into the functional relevance of
ceRNA interactions in complex physiological systems.
Indeed, the effectiveness of ceRNA crosstalk has been
shown to vary in different physiological settings. For ex-
ample, two recent studies examined the effect of seques-
tering the liver-specific miR-122. Denzler et al. analyzed
the stoichiometric relationship between miR-122 and its
targets in hepatocytes in both physiological and patho-
logical conditions [55]. Due to the high expression levels
of miR-122, they found that effective ceRNA crosstalk in
this system could only be mediated by non-physiological
increases in ceRNA levels and that the system was in-
sensitive to up to threefold changes in the miRNA level.
However, even though ceRNA crosstalk was lacking in
physiological conditions for highly abundant miR-122,
the system showed effective ceRNA interaction near the
threshold where miRNA and target levels were near
equimolarity, in agreement with the general consensus
in the field. In contrast, a second study by Luna et al. de-
scribed a quantitative mathematical model of miR-122
sequestration by the hepatitis C virus (HCV) RNA, and
utilized HITS-CLIP and single-cell measurements to
demonstrate that functional sequestration of miR-122 by
the HCV RNA reduced miR-122 binding to its endogen-
ous target mRNAs [56].
These studies present accumulating in silico and in vitro
evidence indicating that the overall stoichiometry of the
interacting molecules and miRNA/ceRNA binding affinity
are critical determinants of effective crosstalk between
ceRNAs in vivo. These factors should be considered when
investigating novel ceRNA transcripts and networks, espe-
cially those of relevance to specific human disease condi-
tions, to facilitate the successful translation of research
results to clinical settings.
Prediction of ceRNA networks in human cancer
Most ceRNA interactions reported to date have been be-
tween a pair of interacting transcripts. However, the ability
of a single miRNA to bind and regulate multiple tran-
scripts and the regulation of a single transcript by multiple
different miRNA molecules allow the effects of relative
changes in miRNA/ceRNA ratios to percolate through
intertwined ceRNETs and affect the expression of distant
ceRNAs. It is thus critical to begin to unravel the com-
plexities of this regulatory crosstalk in genome-scale
ceRNETs.
The availability of genome-wide miRNA-, mRNA-,
and other transcript expression data in large cancer pa-
tient datasets, together with the development of novel
algorithms and bioinformatic tools, enable the in silico
prediction of ceRNA crosstalk. These predictions can be
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potentially generate genome-scale ceRNA network data
for different biological processes, including cancer. Using
this approach, breast and thyroid cancer-specific mRNA
ceRNETs were recently described by two independent
groups [57,58]. Although these results remain to be con-
firmed experimentally, they have proven useful to predict
the risk of metastasis in breast cancer patients [57], and to
highlight specific biological processes that may be central
to certain cancers and regulated by ceRNA crosstalk,
such as immune response regulation in papillary thyroid
carcinoma [58].
Recently, a lncRNA-miRNA-mRNA ceRNET was pre-
dicted computationally in breast cancer patients [59]. This
report found that ceRNETs may be significantly altered
between normal and pathological breast tissues, and
identified the lncRNA PVT1 as a key ceRNA on breast
cancer. A second ceRNET analysis involving lncRNAs
was described using genome-wide expression data from
gastric cancer patients [60]. The authors integrated
microarray data, bioinformatics, and a miRNA target
database to generate a lncRNA-miRNA-mRNA network.
Interestingly, this network contained a high number of
mRNA targets implicated in cancer. Although relevant
experimental validation will be needed to determine the
implications of these findings, the authors showed co-
regulation of the same ceRNAs in independent datasets
from six other cancer types.
Recently, an intriguing new facet of ceRNET dysregu-
lation in cancers was reported. Exome sequencing data
from a large set of prostate cancer patients was analyzed
to examine the effect of alternative cleavage on 3′UTRs
and polyadenylation dynamics on putative ceRNET in-
teractions [61]. Cancer patients could be stratified into
groups with differing risks according to their alternative
polyadenylation profiles, and a ceRNA subnetwork
enriched with prostate cancer genes was found to be
specifically dysregulated only in high-risk cancers. As 3′
UTRs harbor multiple MREs which mediate miRNA
binding, it is perhaps unsurprising that 3′UTR shortening
can affect the associated ceRNETs. However, the obser-
vation that an unusually large number of MREs are
shared between these significantly altered 3′UTRs and
the affected ceRNA interactions suggests that ceRNETs
may indeed be selectively dysregulated in high-risk
prostate cancer.
The potential of studying ceRNA crosstalk in the context
of larger interconnected networks, rather than isolated
ceRNA pair interactions, opens exciting possibilities for the
study of ceRNA-mediated post-transcriptional regulation
in cancer in a setting that is closer to physiological and
pathological conditions. However, there are still several
considerations limiting the practical applicability of ceR-
NET study. One main limitation is the dependence ofmany ceRNA prediction tools on miRNA target prediction
algorithms. Despite improvements in the field, these algo-
rithms are not fool-proof due to our incomplete under-
standing of the rules for miRNA target recognition. This is
particularly relevant for the prediction of mammalian
miRNA and subsequent ceRNA networks, as mammalian
miRNAs often pair with imperfect complementarity to
their target transcripts. Although ceRNA prediction ana-
lysis has been successfully performed using validated
miRNA interactors in the context of PTEN [34], miRNA
target prediction tools were still required to identify bind-
ing of these validated PTEN-targeting miRNAs to potential
ceRNAs of interest.
Additionally, given the scale of high-throughput data
and the number of interactions taken into account, careful
statistical treatment of the data needs to be performed for
global ceRNET study. Moreover, the discovery of novel
ceRNA interactions rely, in many cases, on the significant
co-regulation of transcripts in cancer patient expression
data. However, it has been reported that significant ex-
pression correlation among ceRNAs can emerge in experi-
mental readouts due to transcriptional fluctuations even
in the absence of miRNA-mediated crosstalk [48].
The development of high-throughput experimental val-
idation of ceRNA interactions would thus be central to
the expansion of our knowledge about ceRNETs and
applicability for clinical practice in the future. Recent
advances in techniques enabling the high-throughput se-
quencing of immunoprecipitated RNAs after crosslinking
(such as CLIP-Seq, HITS-CLIP, and PAR-CLIP) provide a
biochemical method to identify relevant miRNA target in-
teractions [56]. For instance, the integration of HITS-
CLIP data with computational approaches was shown to
improve miRNA target prediction by over 20-fold [62]. An
integrated database termed starBase v2.0 has been devel-
oped to identify experimentally supported regulatory
RNA-RNA and protein-RNA interaction networks from
multiple CLIP-Seq datasets [63]. starBase identified about
10,000 ceRNA pairs from CLIP-supported MREs, includ-
ing miRNA-mRNA and miRNA-lncRNA interactions. As
miRNAs, lncRNAs and even mRNAs often display tissue-,
temporal-, and disease-specific expression patterns, such
high-throughput biochemical analyses will be invaluable
to characterize ceRNA interactions in specific cellular
contexts.
Conclusions
In recent years, diverse RNA species including mRNAs,
pseudogenes, small non-coding RNAs, lncRNAs, and
circular RNAs have all been shown to possess ceRNA
activity in defined biological settings. Given the vast
amount of genome-wide transcript expression data, and
advances in the computational management of this pub-
licly available data, we anticipate that reports of the
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tinue to increase. Since miRNA decoying capacity is in-
dependent of protein-coding function, it has been
proposed that the ceRNA activity of coding transcripts
may allow them to exert independent and even opposing
roles to their encoded protein in initiating or maintain-
ing tumorigenic properties [18]. This in turn has import-
ant implications in the study, and potentially the clinical
management, of human cancers. The existence of new
ceRNA transcript classes also represents an exciting area
for future study. Small RNA species such as rRNA and
tRNA have been shown to interact with Argonaute pro-
teins [64], raising the question of whether they could
possess ceRNA activity.
In addition, ceRNA-mediated post-transcriptional regu-
lation has opened the exciting possibility of methodically
studying and functionalizing the non-coding transcrip-
tome. In this respect, the identification of previously
uncharacterized lncRNAs as ceRNA counterparts for
mRNAs is flourishing. Interestingly, protein-coding genes
that produce lncRNAs are over-represented in cancer as-
sociation studies, being twice as likely to be associated to
cancer as human protein-coding genes overall [65]. More-
over, specific regulatory patterns for several lncRNA tran-
scripts have been found for a number of biological
processes [37]. The ceRNA activity of non-coding tran-
scripts may be enhanced by their escape from any form of
interference from the translational machinery. All of this
make lncRNAs great candidates for participating in finely
tuned post-transcriptional regulation.
Most of the work done so far has focused on the study
and quantification of key interacting RNA species such
as miRNAs, mRNAs, lncRNAs, and other ceRNA tran-
scripts. Future work investigating the potential interplay
of ceRNAs with RNA binding proteins (RBPs) will pro-
vide further insights into the complexities of ceRNA
crosstalk. Interestingly, the dynamic recruitment of Ago-
interacting RNA-biding proteins has been shown to alter
miRNA/target affinity [66,67]. A recent report has de-
tailed the development of a database to identify potential
RNA:RNA and RNA:protein regulatory interactions in
multiple CLIP-Seq datasets encompassing miRNA,
mRNA, lncRNA, circRNA, pseudogene, and RBP associ-
ations [63]. Experimental characterization of these RNA:
RBP interactions will be needed to fully understand their
impact on the dynamics of ceRNA interactions.
One of the most exciting advances in the ceRNA field in
recent times has been the potential ability to computation-
ally determine the structure and topology of miRNA and
ceRNA interactions in interconnected ceRNETs, and
harness mathematical modeling to study the dynamic be-
havior of these ceRNETs in response to fluctuations in the
expression of ceRNAs and miRNAs in the network. Fur-
thermore, the quantitative determination of absoluteexpression levels of miRNA and ceRNA molecules ex-
pands the capacity to accurately study the efficiency of
ceRNA crosstalk in diverse physiological and pathological
conditions. We anticipate that the systematic analysis of
ceRNET dynamics would allow for the discovery of new
oligonucleotide gene therapies, targeting highly connected
nodes, which, unlike non-essential players in the network,
may cause severe cellular damage when disrupted [68].
A better understanding of the molecular conditions in
which ceRNA interactions occur is of critical importance to
facilitate the study of this dimension of post-transcriptional
regulation. Fluctuations in both miRNA and ceRNA levels
in vivo need to be carefully examined to determine whether
this dysregulation will lead to significant perturbation of
ceRNA crosstalk in specific biological settings. The in-
tegration of this information with genome-scale ceR-
NET dynamics will be important to determine which
ceRNAs are highly connected target hubs, less likely to
be susceptible to compensation by alternative signaling
pathways.
Multiple mechanisms may contribute to the dysregula-
tion of miRNA and associated ceRNA interactions in
cancer. For example, single nucleotide polymorphisms
(SNPs) located in specific miRNA binding sites have
been shown to modulate the binding of miRNAs to
these target sites. A panel of 30 proto-oncogene associ-
ated SNPs that may impair miRNA target interactions
was recently identified, and a subset of these was further
associated with therapeutic outcome in cancer patients
[69]. In addition to genomic alterations, sequence alter-
ations at the transcript level such as those introduced
through RNA editing have also been shown to effectively
regulate miRNA target specification [70]. The contribu-
tion of such events to the dysregulation of ceRNA net-
works in cancer and potential subsequent impact on
tumor progression and metastasis should be investigated
in future studies.
In conclusion, the study of miRNA and ceRNA net-
works will open up new avenues for basic cancer re-
search, as well as facilitate the development of novel
diagnostic and therapeutic tools. For example, the silen-
cing of aberrantly expressed miRNAs in cancer has been
achieved through antisense oligomers, and recent ad-
vances in targeted delivery to tumor cells have shown
promise in mouse models in vivo [71]. The identification
of key miRNAs and ceRNAs in human cancer may thus
represent promising new therapeutic targets. ceRNA
network components could be targeted alone, to reduce
oncogenic capacity of the cells, or in combination with
traditional therapies to impair acquired drug resistance
through compensatory pathways.Competing interests
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